Back HIV/AIDS HIV/AIDS Topics HIV Treatment

CROI 2017: Time with Transmissible HIV Viral Load Has Fallen By Three-Quarters Since 2000

A study by the Centers for Disease Control and Prevention (CDC) presented at the recent Conference on Retroviruses and Opportunistic Infections in Seattle found that the proportion of time people with HIV in the U.S. spend in care but not virally suppressed has fallen from 40% to 10% in the last 15 years. The study also found that young people, black people, and people with public rather than private health coverage spent less time with viral load below 1500 copies/mL, the World Health Organization (WHO) threshold for HIV transmission.

alt

Read more:

CROI 2017: Treatment-as-Prevention Study Sees Substantial Drug Resistance, but No Impact on HIV Therapy

A study of the prevalence of transmitted drug resistance among participants in the ANRS 12249 trial of treatment as prevention, has found that a substantial minority of participants had HIV with drug resistance mutations. However, there was no evidence that pre-existing drug resistance had any impact on the success of treatment, according to a report at the Conference on Retroviruses and Opportunistic Infections this month in Seattle.

alt

Read more:

CROI 2017: New NNRTI Doravirine Shows Good Efficacy in Phase 3 Study

Doravirine, an investigational next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) from Merck, reduced HIV viral load as well as boosted darunavir in a Phase 3 clinical trial of people starting antiretroviral therapy (ART) for the first time, but it had a better lipid profile, according to a late-breaking presentation at the Conference on Retroviruses and Opportunistic Infections last week in Seattle.

alt

Read more:

CROI 2017: New HIV Capsid Inhibitors Show High Potency and Prolonged Activity in Early Studies

A novel type of antiretroviral drug that interferes with the assembly and disassembly of the HIV capsid, which encloses the genetic blueprint of the virus, may offer a new potent and long-acting treatment option if it continues to look promising in larger studies, according to a presentation at the Conference on Retroviruses and Opportunistic Infections this month in Seattle.

alt

Read more:

CROI 2017: Spanish HIV Vaccine Induces Control Off ART in Nearly 40% of Recipients

A so-called "HIV Conserv" vaccine has, for the first time, produced significant prolonged viral control in a large minority of recipients once they were taken off antiretroviral therapy (ART). So far, 1 participant has stayed off ART for 7 months without having to resume it, according to a report at the Conference on Retroviruses and Opportunistic Infections last week in Seattle.

alt

Read more:

CROI 2017: Monoclonal Antibodies Show Promise for HIV+ People with Few Treatment Options

A pair of long-acting monoclonal antibodies that prevent HIV from entering human cells -- ibalizumab and PRO 140 -- may offer new treatment options for people with highly resistant virus and limited treatment options, researchers reported at the Conference on Retroviruses and Opportunistic Infections (CROI) last week in Seattle.

alt

Read more:

CROI 2017: Changes In Viral Suppression Over Time Reveal Disparities in HIV Care

Sustained viral suppression over the course of a year may be a better measure than the most recent viral load test result when it comes to understanding access to and engagement in HIV care, according a study by Centers for Disease Control and Prevention (CDC) researchers presented at the 2017 Conference on Retroviruses and Opportunistic Infections this week in Seattle.

alt

Read more: